Genetic variants of the nuclear factor erythroid 2-related factor 2/antioxidant reaction element pathway on the risk of antituberculosis drug-induced liver injury: a systematic review

Pharmacogenomics. 2023 Apr;24(6):345-357. doi: 10.2217/pgs-2023-0040. Epub 2023 May 11.

Abstract

Aim: To evaluate the effects of genetic variants in the nuclear factor erythroid 2-related factor 2/antioxidant reaction element signaling pathway on antituberculosis drug-induced liver injury (AT-DILI) susceptibility. Methods: The PubMed, Embase, Cochrane, Web of Science, China National Knowledge Infrastructure and Wanfang databases were searched from inception to April 2022. Results: Seven case-control studies with 4676 patients were included. Six genes with 35 SNPs in the pathway have been reported. Among 17 SNPs reported in two or more studies, the meta-analysis indicated that only one SNP (rs3735656 in MAFK) was significantly associated with a decreased risk for AT-DILI under the dominant model (odds ratio: 0.636; 95% CI: 0.519-0.780; p < 0.001). Conclusion: SNP rs3735656 in the MAFK gene was significantly associated with the risk of AT-DILI.

Keywords: Nrf2/ARE pathway; antituberculosis drug-induced liver injury; genetic variants; meta-analysis.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Antioxidants*
  • Case-Control Studies
  • Chemical and Drug Induced Liver Injury* / genetics
  • China
  • Genetic Predisposition to Disease
  • Humans
  • NF-E2-Related Factor 2
  • Polymorphism, Single Nucleotide / genetics

Substances

  • Antioxidants
  • NF-E2-Related Factor 2